AR012014A1 - Composiciones para tratamiento de un dia de enfermedades mediadas por ciclooxigenasa-2 - Google Patents
Composiciones para tratamiento de un dia de enfermedades mediadas por ciclooxigenasa-2Info
- Publication number
- AR012014A1 AR012014A1 ARP970102021A ARP970102021A AR012014A1 AR 012014 A1 AR012014 A1 AR 012014A1 AR P970102021 A ARP970102021 A AR P970102021A AR P970102021 A ARP970102021 A AR P970102021A AR 012014 A1 AR012014 A1 AR 012014A1
- Authority
- AR
- Argentina
- Prior art keywords
- cyclooxygenase
- treatment
- compound
- directed
- mediated diseases
- Prior art date
Links
- 108010037462 Cyclooxygenase 2 Proteins 0.000 title abstract 6
- 201000010099 disease Diseases 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 230000001404 mediated effect Effects 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 102000010907 Cyclooxygenase 2 Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108010037464 Cyclooxygenase 1 Proteins 0.000 abstract 1
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 abstract 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 abstract 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta invencion está dirigida a composiciones farmacéuticas para el tratamiento de enfermedades mediadas por ciclooxigenasa-2, dicha composicionsiendo apropiada para una administracion diaria, dicha composicion comprende un compuestoinhib idor de ciclooxigenasa-2 caracterizado por alta potencia,una larga vida media y un alto grado de especificidad para inhibir ciclooxigenasa-2 en preferencia a ciclooxigenasa-1. Tal compuesto esejemplificado por 3-fenil-4-(4-metilsulfonil) fenil)-2-(5H)-furanona. En un aspecto, esta invencion es dirigida a las composiciones farmacéuticas parael tratamiento de enfermedades mediadas por ciclooxigenasa-2, dicha composicion siendo apropiada para una administraciondiaria, dicha compos icion comprende de5 a 125 mg del compuesto arriba mencionado. La invencion es también dirigida a un método para el tratamiento de enfermedades mediadas por ciclooxigenasa-2que comprende una administracion oral diaria de 5 a125 mg del compuesto ar riba mencionado. La invencion es también dirigida al uso del mencionado compuestoen la manufactura de un medicamento que contiene 5 a 125 mg de dicho compuesto para una administracion diaria para el tratamiento deenfermedades mediadas porciclooxige nasa-2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1787896P | 1996-05-17 | 1996-05-17 | |
| GBGB9612063.9A GB9612063D0 (en) | 1996-06-10 | 1996-06-10 | Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR012014A1 true AR012014A1 (es) | 2000-09-27 |
Family
ID=26309472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970102021A AR012014A1 (es) | 1996-05-17 | 1997-05-14 | Composiciones para tratamiento de un dia de enfermedades mediadas por ciclooxigenasa-2 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6063811A (es) |
| EP (1) | EP0910368A1 (es) |
| JP (1) | JPH11512754A (es) |
| KR (1) | KR100373622B1 (es) |
| CN (1) | CN1140267C (es) |
| AR (1) | AR012014A1 (es) |
| AU (1) | AU3004997A (es) |
| BG (1) | BG103000A (es) |
| BR (1) | BR9709097A (es) |
| CA (1) | CA2254061C (es) |
| CO (1) | CO5050370A1 (es) |
| CZ (1) | CZ291463B6 (es) |
| DZ (1) | DZ2200A1 (es) |
| EA (1) | EA001596B1 (es) |
| EE (1) | EE03746B1 (es) |
| HK (1) | HK1021623A1 (es) |
| HR (1) | HRP970262A2 (es) |
| HU (1) | HUP9902889A3 (es) |
| ID (1) | ID16921A (es) |
| IL (1) | IL126899A (es) |
| IS (1) | IS4891A (es) |
| MY (1) | MY116201A (es) |
| NO (1) | NO985342D0 (es) |
| NZ (1) | NZ332670A (es) |
| PE (1) | PE66998A1 (es) |
| PL (1) | PL188649B1 (es) |
| SK (1) | SK284330B6 (es) |
| TR (1) | TR199802345T2 (es) |
| WO (1) | WO1997044028A1 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2322824A1 (en) * | 1998-03-13 | 1999-09-16 | Merck & Co., Inc. | Combination therapy and composition for acute coronary ischemic syndrome and related conditions |
| US6136804A (en) * | 1998-03-13 | 2000-10-24 | Merck & Co., Inc. | Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions |
| SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
| CO5190664A1 (es) | 1999-06-30 | 2002-08-29 | Pfizer Prod Inc | Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2 |
| GB9920558D0 (en) * | 1999-08-31 | 1999-11-03 | Bradford Particle Design Ltd | Methods for particle formation and their products |
| PL355391A1 (en) * | 1999-12-22 | 2004-04-19 | Pharmacia Corporation | Sustained-release formulation of a cyclooxygenase-2 inhibitor |
| CA2411960C (en) | 2000-06-13 | 2010-10-12 | Wyeth | Analgesic and anti-inflammatory compositions containing cox-2 inhibitors |
| CN1638739A (zh) * | 2000-08-18 | 2005-07-13 | 法玛西雅厄普约翰美国公司 | 治疗成瘾性障碍的化合物 |
| NZ524124A (en) * | 2000-08-18 | 2004-09-24 | Pharmacia Corp | Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor |
| WO2002017896A2 (en) * | 2000-08-29 | 2002-03-07 | Peter Van Patten | Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid |
| PE20020351A1 (es) * | 2000-09-11 | 2002-06-14 | Novartis Ag | Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2 |
| US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| CA2445502A1 (en) * | 2001-05-04 | 2002-11-14 | Merck & Co., Inc. | Method and compositions for treating migraines |
| PE20030323A1 (es) * | 2001-08-31 | 2003-05-12 | Novartis Ag | Composicion farmaceutica |
| IL160855A0 (en) * | 2001-09-26 | 2004-08-31 | Pharmacia Corp | Intraorally disintegrating valdecoxib compositions |
| OA12666A (en) * | 2001-10-10 | 2006-06-19 | Pharmacia Corp Corporate Paten | Intraorally disintegrating valdecoxib compositionsprepared by spray drying process. |
| BR0308156A (pt) * | 2002-03-07 | 2005-01-04 | Novartis Ag | Composições farmacêuticas sólidas contendo lumiracoxib |
| ES2213485B1 (es) | 2003-02-13 | 2005-12-16 | Almirall Prodesfarma, S.A. | Derivados de la 2-fenilpiran-4-ona. |
| ES2214129B1 (es) * | 2003-02-13 | 2005-12-01 | Almirall Prodesfarma, S.A. | 3-fenilfuran-2-onas. |
| EP1745791B1 (en) | 2003-05-07 | 2013-06-26 | Osteologix A/S | Treating cartilage/bone conditions with water-soluble strontium salts |
| TR200301552A1 (tr) * | 2003-09-18 | 2005-10-21 | Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. | Rofekoksib' in yeni oral farmakolojik formülasyonları. |
| JP2010516679A (ja) * | 2007-01-19 | 2010-05-20 | マリンクロット インコーポレイテッド | 診断用および治療用シクロオキシゲナーゼ−２結合リガンド |
| JP7291220B2 (ja) | 2018-11-21 | 2023-06-14 | トレモ― ファーマシューティカルズ，インコーポレーテッド | ロフェコキシブの精製形態、製造方法および使用 |
| US20200323830A1 (en) * | 2019-04-09 | 2020-10-15 | Tremeau Pharmaceuticals, Inc. | Treatment of viral hemorrhagic fevers with etoricoxib |
| US10945992B1 (en) | 2019-11-13 | 2021-03-16 | Tremeau Pharmaceuticals, Inc. | Dosage forms of rofecoxib and related methods |
| US11161833B1 (en) | 2021-04-09 | 2021-11-02 | Tremeau Pharmaceuticals, Inc. | Deuterated etoricoxib, methods of manufacture, and use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| SG43841A1 (en) * | 1994-01-10 | 1997-11-14 | Merck Frosst Canada Inc | Phenyl heterocycles as cox-2 inhibitors |
-
1997
- 1997-05-13 US US09/180,647 patent/US6063811A/en not_active Expired - Lifetime
- 1997-05-13 HU HU9902889A patent/HUP9902889A3/hu unknown
- 1997-05-13 EA EA199801017A patent/EA001596B1/ru not_active IP Right Cessation
- 1997-05-13 JP JP9542486A patent/JPH11512754A/ja active Pending
- 1997-05-13 SK SK1567-98A patent/SK284330B6/sk unknown
- 1997-05-13 BR BR9709097A patent/BR9709097A/pt not_active IP Right Cessation
- 1997-05-13 CA CA002254061A patent/CA2254061C/en not_active Expired - Fee Related
- 1997-05-13 TR TR1998/02345T patent/TR199802345T2/xx unknown
- 1997-05-13 EE EE9800393A patent/EE03746B1/xx not_active IP Right Cessation
- 1997-05-13 WO PCT/US1997/008041 patent/WO1997044028A1/en not_active Application Discontinuation
- 1997-05-13 KR KR10-1998-0709239A patent/KR100373622B1/ko not_active IP Right Cessation
- 1997-05-13 CN CNB971963150A patent/CN1140267C/zh not_active Expired - Fee Related
- 1997-05-13 IL IL12689997A patent/IL126899A/en not_active IP Right Cessation
- 1997-05-13 CZ CZ19983738A patent/CZ291463B6/cs not_active IP Right Cessation
- 1997-05-13 EP EP97924688A patent/EP0910368A1/en not_active Withdrawn
- 1997-05-13 AU AU30049/97A patent/AU3004997A/en not_active Abandoned
- 1997-05-13 NZ NZ332670A patent/NZ332670A/xx unknown
- 1997-05-14 AR ARP970102021A patent/AR012014A1/es unknown
- 1997-05-14 DZ DZ970087A patent/DZ2200A1/fr active
- 1997-05-15 PE PE1997000379A patent/PE66998A1/es not_active Application Discontinuation
- 1997-05-16 MY MYPI97002138A patent/MY116201A/en unknown
- 1997-05-16 CO CO97026568A patent/CO5050370A1/es unknown
- 1997-05-16 ID IDP971640A patent/ID16921A/id unknown
- 1997-05-16 HR HR9612063.9A patent/HRP970262A2/xx not_active Application Discontinuation
-
1998
- 1998-11-10 IS IS4891A patent/IS4891A/is unknown
- 1998-11-16 NO NO985342A patent/NO985342D0/no not_active Application Discontinuation
- 1998-12-08 BG BG103000A patent/BG103000A/xx unknown
-
1999
- 1999-01-11 PL PL97329940A patent/PL188649B1/pl not_active IP Right Cessation
-
2000
- 2000-02-02 HK HK00100645A patent/HK1021623A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR012014A1 (es) | Composiciones para tratamiento de un dia de enfermedades mediadas por ciclooxigenasa-2 | |
| ATE362755T1 (de) | Stabile n-propargyl-1-aminoindan enthaltende zusammensetzungen | |
| DK0828724T3 (da) | 5-oxygenerede diaryl-2-(5H)-furanoner som COX-2-inhibitorer | |
| IS4695A (is) | (Metýlsúlfónýl)fenýl-2-(5H)-fúranón sem sýklóoxýgenasa-2 tálmar | |
| DK0688214T3 (da) | Fremgangsmåder til inhibering af knogletab med 3,4-diarylchroman | |
| CO5180579A1 (es) | Composicion oral solida que comprende levidopa, carbidopa y entacapone | |
| CY1113191T1 (el) | Συνθεση συμπιεσμενων δισκιων εφαβιρενζης | |
| BR9406979A (pt) | Composto,composicão farmaceutica para tratar uma doenca inflamatória suscetivel de tratamento com um agente anti- inflamatório nao esteroidal processos para tratar uma doenca inflamatória e para preparar um composto sal famacéuticamente aceitável uso de um composto composicão farmaceutica anti-inflamatória nao esteroidal | |
| ATE297203T1 (de) | Antithrombotische mitteln | |
| EA200201271A1 (ru) | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 | |
| LU91254I2 (fr) | Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr) | |
| HUP0100043A2 (hu) | Savérzékeny hatóanyagot tartalmazó új gyógyszerforma | |
| DK2295052T3 (da) | Anvendelse af ritonavir til forbedring af farmakokinetikken af lægemidler, der metaboliseres af cytochrom P450 | |
| PT948527E (pt) | Novos derivados de ciclosporina sua preparacao e composicoes farmaceuticas que os contem | |
| EP0999834A4 (en) | ANTITHROMOSIS | |
| AR045572A1 (es) | Una combinacion que comprende n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil-3-sulfonamida y un analogo lhrh y/o un bifosfonato | |
| GT199700037A (es) | Composiciones farmaceuticas para el tratamiento de la rinitis | |
| BR0111678A (pt) | Composições medicinais contendo derivados de propenona | |
| IT1272149B (it) | Composizione farmeceutiche ad attivita' analgesica | |
| CR5926A (es) | Combinaciones de estatina-eter carboxialquilico | |
| DK0701449T3 (da) | Fremgangsmåde til fremstilling af en oral fast dosisform indeholdende diclofenac | |
| YU43996A (sh) | Upotreba duloksetina za proizvodnju leka i njegova farmaceutska kompozicija | |
| AU7270798A (en) | Antithrombotic agents | |
| AR006281A1 (es) | Utilizacion de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4- piperidinometanol o sus sales de adicion de acidos farmaceuticamenteaceptables en el tratamineto de trastornos depresivos y trastornos bipolares | |
| ECSP972123A (es) | Composiciones para un tratamiento de una sola vez de enfermedades en que intervienen la ciclooxigenasa- 2 - |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |